| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/18/2002 | US20020094954 Nucleic acids comprising the neuregulin-1-associated gene 1 (NRG1AG1) |
| 07/18/2002 | US20020094952 Human therapeutic uses of BPI Protein products |
| 07/18/2002 | US20020094948 To treat anemias or hemodialysis patients; individual dosage forms |
| 07/18/2002 | US20020094542 Drugs and methods for treating cancer |
| 07/18/2002 | US20020094524 Preventing preferential viral disease; obtain human, administer an antagonist of neurokinin receptors, monitor humans for reduced viral activity |
| 07/18/2002 | US20020094440 Implant with coating of copolymer of vinylidenefluoride (VDF) and/or tetrafluoroethylene (TFE) with another monomer in amounts effective to reduce thrombosis and/or restenosis when such stents are used in, e.g. angioplasty procedures |
| 07/18/2002 | US20020094351 Administering wikstromol ( 4,4,8-trihydroxy-3, 31-dimethoxyliganan-9, 91-olide) to the patient for the prevention of hepatotoxicity |
| 07/18/2002 | US20020094328 Combination of lactic acid bacteria and its use for the prevention and/or treatment of infections and inflammatory conditions |
| 07/18/2002 | US20020094323 Administration of reactive oxygen species inhibitor or scavenger and at least one monocyte maturation-promoting agent |
| 07/18/2002 | US20020092539 Hair clip |
| 07/18/2002 | DE10102053A1 Piperazinylcarbonyl-quinoline and piperazinylcarbonyl-isoquinoline derivatives useful for treatment of e.g. schizophrenia, psychoses, depression, Parkinson's disease and Alzheimer's disease |
| 07/18/2002 | CA2725833A1 Spaced drug delivery system |
| 07/18/2002 | CA2697520A1 Use of lyophilised reduced diaminophenothiazines in the treatment of tau mediated neurological disorders |
| 07/18/2002 | CA2436876A1 Transcriptional mediators of blood vessel development and endothelial differentiation |
| 07/18/2002 | CA2436814A1 Intravascular drug delivery device and use therefor |
| 07/18/2002 | CA2434672A1 Sfrp and peptide motifs that interact with sfrp and methods of their use |
| 07/18/2002 | CA2434402A1 Modular transfection systems |
| 07/18/2002 | CA2434330A1 Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands |
| 07/18/2002 | CA2434269A1 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms |
| 07/18/2002 | CA2434171A1 Therapeutic modulation of the tumor inflammatory response |
| 07/18/2002 | CA2434005A1 Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and their use as purinergic receptor antagonists |
| 07/18/2002 | CA2433723A1 Chemical derivatives and their use as anti-telomerase agent |
| 07/18/2002 | CA2433656A1 Hormone replacement therapy method and its administration form |
| 07/18/2002 | CA2433653A1 Regulation of lipids and/or bone density and compositions therefor |
| 07/18/2002 | CA2433652A1 Active metabolite of antifungal compound |
| 07/18/2002 | CA2433623A1 Pyridine derivatives useful as cyclooxygenase inhibitor |
| 07/18/2002 | CA2433451A1 Use of an ltb4 antagonist for the treatment and/or prevention of diseases caused by increased expression of mucin genes |
| 07/18/2002 | CA2432114A1 4-(hetero)aryl substituted indolinones |
| 07/18/2002 | CA2430060A1 Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancer |
| 07/18/2002 | CA2427840A1 Methods of using imxp-888 and imxp-888 antagonists |
| 07/17/2002 | EP1223176A2 Peptide mutant of human ERAB/HADH2, its X-ray crystal structure, and materials and method for identification of inhibitors thereof |
| 07/17/2002 | EP1222927A2 Pharmaceutical compositions having appetite suppressant activity |
| 07/17/2002 | EP1222913A1 Depilatories and agents for external use |
| 07/17/2002 | EP1222683A1 Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease |
| 07/17/2002 | EP1222466A2 Method to identify compounds which modulate fra-1 expression fils |
| 07/17/2002 | EP1222463A2 Allosteric sites on muscarinic receptors |
| 07/17/2002 | EP1222459A1 Crystallographic structure of the androgen receptor ligand binding domain |
| 07/17/2002 | EP1222313A2 Genes associated with obesity and methods for using the same |
| 07/17/2002 | EP1222308A1 Antiprotozoal histone acetyl transferase inhibitors |
| 07/17/2002 | EP1222284A2 22196, a novel human aminopeptidase |
| 07/17/2002 | EP1222279A2 Growth factor polypeptides and nucleic acids encoding same |
| 07/17/2002 | EP1222266A2 Pca3 messenger rna species in benign and malignant prostate tissues |
| 07/17/2002 | EP1222226A1 Highly-neutralized ethylene copolymers and their use in golf balls |
| 07/17/2002 | EP1222206A1 Pablo, a polypeptide that interacts with bcl-xl, and uses related thereto |
| 07/17/2002 | EP1222204A1 A DNA MOLECULE ENCODING A VARIANT $g(a) 2B?-ADRENOCEPTOR PROTEIN, AND USES THEREOF |
| 07/17/2002 | EP1222186A2 Condensed naphthyridines as hiv reverse transcriptase inhibitors |
| 07/17/2002 | EP1222171A1 Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof |
| 07/17/2002 | EP1221977A2 Tumor detection by imaging and therapy of tumors |
| 07/17/2002 | EP1221974A2 Magnetic targeted carrier |
| 07/17/2002 | EP1221973A1 CD40 antagonist for treating psoriasis |
| 07/17/2002 | EP1221963A1 Methods of inhibiting osteoclastogenesis |
| 07/17/2002 | EP1221962A2 Inhibitors of proteasomal activity for stimulating bone and hair growth |
| 07/17/2002 | EP1221955A2 Immunostimulatory nucleic acids |
| 07/17/2002 | EP1221953A1 Treating sleep disorders using desloratadine |
| 07/17/2002 | EP1221950A1 Synergistic combinations of an nk 1? receptor antagonist and a gaba structural analog |
| 07/17/2002 | EP1221949A2 Method and composition for prophylaxis and treatment of symptoms associated with cold and influenza-like illnesses |
| 07/17/2002 | EP1221939A1 Ortho ester lipids |
| 07/17/2002 | EP1221926A1 Pharmaceutical formulations containing poorly soluble drug substances |
| 07/17/2002 | EP1221917A1 Drug delivery device |
| 07/17/2002 | EP1221908A1 Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| 07/17/2002 | EP1221865A2 Food supplement for increasing lean mass and strength |
| 07/17/2002 | EP1221861A1 Fat or oil composition |
| 07/17/2002 | EP1221847A1 Methods of enhancing chemotherapy |
| 07/17/2002 | EP1221845A1 Active ingredient combinations having insecticidal and acaricidal properties |
| 07/17/2002 | EP1146891A4 Inhibiting development of microvessels within vascular walls |
| 07/17/2002 | EP1115887A4 Parallel selex |
| 07/17/2002 | CN1359381A Thiazole-derivaties |
| 07/17/2002 | CN1359376A Carboxylic acid derivatives compriosing aryl-substituted nitrogen heterocycles, their production and their use as endothel in receptor antagonists |
| 07/17/2002 | CN1359370A Esters of L-carnitine or alkanoyl L-carnitines |
| 07/17/2002 | CN1359302A Remedies for immunoogical diseases |
| 07/17/2002 | CN1359297A Method for preventing tumoral growth |
| 07/17/2002 | CN1359293A Pharmaceutical compositions comprising dipeptidy peptidase in inhibitors for the promotion of growth |
| 07/17/2002 | CN1359289A Selective iGLuR5 receptor antagonists for the treatment of migraine |
| 07/17/2002 | CN1359288A Method for improvement of transport across adaptable semi-permeable barriers |
| 07/17/2002 | CN1359262A Therapeutic anti-fungal nail preparation |
| 07/16/2002 | US6420591 Carbamates and compositions thereof, and methods for their use for treating cancer, inflammation, or a viral infection |
| 07/16/2002 | US6420545 Nucleotide sequences coding polypeptide for use in the treatment of preferential viral diseases |
| 07/16/2002 | US6420542 Tie ligands |
| 07/16/2002 | US6420532 Binding to human y2 receptors and expression |
| 07/16/2002 | US6420433 S(+) desmethylselegiline and drug withdrawal |
| 07/16/2002 | US6420432 Surgical irrigation solution and method for inhibition of pain and inflammation |
| 07/16/2002 | US6420431 Methods for treating disordered tissue through agitated delivery of anti-infective compositions |
| 07/16/2002 | US6420430 Use of benzoylguanidine derivatives to prevent aging disorders |
| 07/16/2002 | US6420426 Used to treat complications from diabetes mellitus |
| 07/16/2002 | US6420420 Method for increasing the concentration of ascorbic acid in brain tissue of a subject |
| 07/16/2002 | US6420417 Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
| 07/16/2002 | US6420405 Pharmaceutical composition for angiotensin II-mediated diseases |
| 07/16/2002 | US6420402 Blocking of associated non-inactivating sodium channels in retinal ganglion cells in order to limit sodium/calcium exchange in retinal ganglion cells and prevent buildup of calcium level in retinal ganglion cells to a lethal level |
| 07/16/2002 | US6420394 Topically applied pharmaceutical formulation |
| 07/16/2002 | US6420382 Tyrosine kinase inhibitors |
| 07/16/2002 | US6420378 Synergistic effects of 9-nitro-20(s)-camptothecin and an antibody, antitumor |
| 07/16/2002 | US6420376 Amido spiropiperidines promote the release of growth hormone |
| 07/16/2002 | US6420352 Hair loss prevention |
| 07/16/2002 | US6420351 Administering mixture of alanine, serine, methylglycine and cycloserine |
| 07/16/2002 | US6420338 Hepatitis b virus (hbv); hepatocellular carcinoma |
| 07/16/2002 | US6420335 Cancer therapy; angiostatin or endostatin to sensitize tumor endothelial cells to ionizing radiation |
| 07/16/2002 | US6420176 Composition for delivering DNA into antigen presenting cells |
| 07/16/2002 | US6420171 Composite material for use in the isolation of aggregations of cells associate with preferential blood disorders |
| 07/16/2002 | US6420161 Nucleotide sequences coding enzymatic polypeptide for use in screening bactericides |
| 07/16/2002 | US6420150 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |